CRESCENT BIOPHARMA, INC. (CBIO) SEC Filings & Earnings Calls

Clinical trial risk: no data reported yet; all timelines are forward-looking and subject to change.

“Initial monotherapy data from ASCEND expected in Q1 2027; combination data in mid-2027; Phase 3 initiation planned for early 2028 pending results.”

Going concern risk / capital requirement

“We will need to raise substantial additional capital to continue to fund our operations in the future.” · word for word

Clinical development risk

“We are a clinical-stage biotechnology company with a limited operating history; we have not completed any clinical trials, have no products approved for commercial sale.” · word for word

Competitive risk

“We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, including Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Summit Therapeutics Inc., BioNTech SE, LaNova Medicines Ltd., and Compass Therapeutics, Inc.” · word for word

Dependence on lead program CR-001

“Our future success is substantially dependent on our ability to timely obtain regulatory approval for, and then successfully commercialize, our lead program, CR-001.” · word for word

Pre-revenue clinical-stage biotech with no approved products; depends on trial success and financing.

“No revenue or net income reported; cash burn from R&D; reliance on pipeline milestones.”

Clinical trial risk: failure of CR-001, CR-002, or CR-003 could impair pipeline value.

“All programs in Phase 1/2; no approved products; data readouts not until 2027.”

Dilution risk from equity offering and potential warrant conversion.

“Public offering of ordinary shares and pre-funded warrants; dilution to existing shareholders.”

Pre-revenue biotech with significant R&D spend and no approved products; cash runway into 2028 but dependent on pipeline success.

“Net loss $23.3M; R&D $17.9M; no product revenue.”

Clinical trial risk: ASCEND trial data not expected until 2027; potential delays or negative readouts.

“Proof-of-concept data from ASCEND trial expected in Q1 2027.”

Going concern risk due to continued losses and no product revenue

“We have historically incurred losses and we anticipate that we will continue to incur losses for the foreseeable future. We have never generated revenue from product sales and may never be profitable.” · word for word

Dependence on lead program CR-001

“We are substantially dependent on the success of our lead program, CR-001, and our current and anticipated clinical trials of such program may not be successful.” · word for word

In-licensed patent portfolio risk

“We do not currently own any issued patents and our patent portfolio is in-licensed from Paragon Therapeutics, Inc, and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.” · word for word

Concentrated voting control by Fairmount

“These two Preferred Directors, in the aggregate, have six votes on each matter presented to the Board, representing 60% of the total votes of the Board. As a result, these two Preferred Directors are able to control or significantly influence all matters submitted to our Board for approval.”

No product revenue and significant losses

“We have never generated revenue from product sales and may never be profitable.”

Dependence on Paragon and Kelun for intellectual property

“We do not currently own any issued patents and our patent portfolio is in-licensed from Paragon Therapeutics, Inc, and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.”

Preclinical-stage with no revenue and significant losses

“We are a preclinical-stage biotechnology company with a limited operating history on which to assess our business; we have not completed any clinical trials, have no products approved for commercial sale, have historically incurred losses, and we anticipate that we will continue to incur significant losses for the foreseeable future.”

Substantial doubt about going concern / need for additional capital

“We will need to raise substantial additional capital to continue to fund our operations in the future.”

Dependence on lead program CR-001 and preclinical stage

“We are substantially dependent on the success of our lead program, CR-001, and our anticipated clinical trials of such program may not be successful.”

Potential dilution from future equity financings

“To the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest of our shareholders will be diluted.”

Intense competition from larger companies

“We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, including Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Summit Therapeutics Inc., BioNTech SE, LaNova Medicines Ltd., and Compass Therapeutics, Inc.”

Clinical-stage biotech with no approved products; significant R&D spending; reliance on pipeline success.

“R&D expenses were $138.1 million and $14.0 million for the twelve months ended December 31, 2025 and the period from September 19, 2024 (inception) through December 31, 2024, respectively.”

Partnership dependency: Revenue from Kelun-Biotech upfront payment; collaboration risks.

“The revenue recognized in 2025 is the result of the $20.0 million upfront payment received from Kelun-Biotech pursuant to the license agreement for CR-001.” · word for word

Preclinical-stage with no revenue and significant losses

“We are a preclinical-stage biotechnology company with a limited operating history on which to assess our business; we have not initiated, conducted, or completed any clinical trials, have no products approved for commercial sale, have historically incurred losses, and anticipates that we will continue to incur significant losses for the foreseeable future.” · word for word

Substantial doubt about going concern / need for additional capital

“We will need to raise substantial additional capital to continue to fund our operations in the future.” · word for word

Dependence on lead program CR-001 and preclinical stage

“We are substantially dependent on the success of our lead program, CR-001, and our anticipated clinical trials of such program may not be successful.” · word for word

Potential dilution from future equity financings

“To the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest of our shareholders will be diluted.” · word for word

Intense competition from larger companies

“We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, including Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Summit Therapeutics Inc., BioNTech SE, LaNova Medicines Ltd., and Compass Therapeutics, Inc.” · word for word

Pre-revenue biotech with no approved products; clinical trial failure risk.

“No revenue; net loss $24.6M; forward-looking statements highlight risks.”

Dependence on successful IND filings and clinical trials for CR-001 and CR-002.

“IND for CR-001 on track Q4 2025; CR-002 IND mid-2026; no clinical data yet.”